NCT02371174

Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.

An Observational Post-Marketing Surveillance Study on the Status and Factors for the Development of Peripheral Neuropathy in Patients With HER2-Negative Inoperable or Recurrent Breast Cancer in Japan.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 651 (actual)
• Sponsor: Eisai Co., Ltd. · Industry
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

The primary objective of the study is to clarify factors affecting the incidence of peripheral neuropathy in patients treated with HALAVEN. A total of 590 patients will be enrolled in this study with 295 patients in the treatment group of primary or secondary chemotherapy and 295 patients in the treatment group of tertiary or later chemotherapy.

Conditions

• Breast Cancer
• HER2-negative Breast Cancer

Timeline

• Start date: 2014-09-03
• Primary completion: 2018-01-21
• Completion: 2018-01-21
• First posted: 2015-02-25
• Last updated: 2018-07-13

Locations

2 sites across 1 country: Japan